NeoGenomics, Inc. (NasdaqCM:NEO) is looking for M&A. Jeffrey Sherman Chief Financial Officer said during the First Quarter 2024 Financial Results Conference Call and Webcast, "Our strong cash position gives us the financial flexibility to address our 2025 convertible notes, with a principal balance of $201 million maturing in May 2025. These notes will become current liabilities on our balance sheet in the second quarter. Given our liquidity profile, our current expectation is to use our existing cash and marketable securities to retire the 2025 convertible notes when they mature.

However, we are starting to evaluate strategic M&A opportunities, which could ultimately impact our capital structure decisions".